Profile data is unavailable for this security.
About the company
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of T cell-driven inflammatory diseases. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Ra) in development for the treatment of atopic dermatitis and asthma. Its second advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with atopic dermatitis (AD). It has clinical development activities in the United States, the People’s Republic of China (PRC), Europe, and Australia and operations in those geographies, as well as Hong Kong. Its subsidiaries include Connect Biopharma HongKong Limited, Connect Biopharm LLC and others.
- Revenue in USD (TTM)0.00
- Net income in USD-59.50m
- Incorporated2015
- Employees81.00
- LocationConnect Biopharma Holdings Ltd12265 El Camino Real, Suite 350SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 727-1040
- Websitehttps://www.connectbiopharm.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LAVA Therapeutics NV | 6.77m | -41.97m | 72.03m | 37.00 | -- | 1.41 | -- | 10.64 | -1.58 | -1.58 | 0.2532 | 1.95 | 0.0552 | -- | 2.87 | 182,946.00 | -34.25 | -- | -40.31 | -- | 48.56 | -- | -620.09 | -- | -- | -- | 0.1098 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -10.49m | 72.35m | 2.00 | -- | 11.15 | -- | -- | -0.4087 | -0.4087 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -86.04 | -- | -95.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
| Celularity Inc | 14.79m | -181.41m | 73.63m | 225.00 | -- | 2.16 | -- | 4.98 | -10.51 | -10.51 | 0.8376 | 1.56 | 0.0498 | 2.29 | 2.03 | 65,724.45 | -61.05 | -- | -82.37 | -- | 21.19 | -- | -1,226.72 | -- | 0.1366 | 18.40 | 0.5365 | -- | -15.75 | -- | 114.18 | -- | -- | -- |
| Assembly Biosciences Inc | 7.16m | -61.23m | 73.91m | 65.00 | -- | 1.80 | -- | 10.32 | -14.02 | -14.02 | 1.63 | 7.50 | 0.06 | -- | 14.51 | 110,200.00 | -51.32 | -39.69 | -66.88 | -44.03 | -- | -- | -854.78 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -27.03m | 74.05m | 28.00 | -- | 1.91 | -- | -- | -0.5642 | -0.5642 | 0.00 | 0.7889 | 0.00 | -- | -- | 0.00 | -47.51 | -38.31 | -56.21 | -43.34 | -- | -- | -- | -- | -- | -6.33 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Bakhu Holdings Corp | 0.00 | -1.92m | 75.33m | 2.00 | -- | -- | -- | -- | -0.0064 | -0.0064 | 0.00 | -0.0325 | 0.00 | -- | -- | 0.00 | -281.75 | -4,391.82 | -- | -- | -- | -- | -- | -- | -- | -8.39 | -- | -- | -- | -- | 33.37 | -- | -- | -- |
| Connect Biopharma Holdings Ltd (ADR) | 0.00 | -59.50m | 75.49m | 81.00 | -- | 0.7797 | -- | -- | -1.08 | -1.08 | 0.00 | 1.76 | -- | -- | -- | 0.00 | -- | -66.24 | -- | -71.36 | -- | -- | -- | -- | -- | -- | 0.0046 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
| Tempest Therapeutics Inc | 0.00 | -29.49m | 76.34m | 17.00 | -- | 2.83 | -- | -- | -1.96 | -1.96 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -60.38 | -57.10 | -72.81 | -71.20 | -- | -- | -- | -- | -- | -87.30 | 0.2827 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Passage Bio Inc | 0.00 | -102.06m | 76.40m | 58.00 | -- | 0.6122 | -- | -- | -1.87 | -1.87 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -51.80 | -48.56 | -56.80 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Spero Therapeutics Inc | 103.78m | 22.81m | 76.53m | 46.00 | 3.50 | 0.7041 | 3.30 | 0.7374 | 0.4055 | 0.4055 | 1.96 | 2.02 | 0.6757 | -- | 4.01 | 2,256,087.00 | 14.85 | -35.52 | 18.36 | -41.75 | -- | -- | 21.98 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| vTv Therapeutics Inc | 0.00 | -20.25m | 76.76m | 16.00 | -- | -- | -- | -- | -9.79 | -9.79 | 0.00 | -9.27 | 0.00 | -- | -- | 0.00 | -117.34 | -111.84 | -1,613.30 | -- | -- | -- | -- | -680.94 | -- | -- | -- | -- | -100.00 | -- | -5.67 | -- | -- | -- |
| Athira Pharma Inc | 0.00 | -117.67m | 77.04m | 65.00 | -- | 0.5894 | -- | -- | -3.09 | -3.09 | 0.00 | 3.41 | 0.00 | -- | -- | 0.00 | -56.25 | -30.73 | -63.93 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -25.79m | 77.61m | 25.00 | -- | 2.62 | -- | -- | -0.8564 | -0.8564 | 0.00 | 0.7609 | 0.00 | -- | -- | 0.00 | -60.26 | -- | -76.27 | -- | -- | -- | -- | -- | -- | -1,878.67 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -31.05m | 78.81m | 43.00 | -- | 5.77 | -- | -- | -0.6825 | -0.6825 | 0.00 | 0.2529 | 0.00 | -- | -- | -- | -84.76 | -70.19 | -97.55 | -78.31 | -- | -- | -- | -15,434.15 | 0.7822 | -42.08 | 0.4717 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
Data as of Apr 24 2024. Currency figures normalised to Connect Biopharma Holdings Ltd's reporting currency: US Dollar USD
7.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 31 Dec 2023 | 2.06m | 3.74% |
| BlackRock Advisors LLCas of 31 Dec 2023 | 1.04m | 1.89% |
| UBS O'Connor LLCas of 31 Dec 2023 | 561.19k | 1.02% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 298.00k | 0.54% |
| Andbank Wealth Management SGIIC SAUas of 30 Jun 2023 | 30.00k | 0.05% |
| Geode Capital Management LLCas of 31 Dec 2023 | 27.96k | 0.05% |
| RhumbLine Advisers LPas of 31 Dec 2023 | 16.52k | 0.03% |
| XTX Markets LLCas of 31 Dec 2023 | 15.51k | 0.03% |
| Two Sigma Securities LLCas of 31 Dec 2023 | 12.31k | 0.02% |
| Two Sigma Investments LPas of 31 Dec 2023 | 11.41k | 0.02% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
